外资态度来看，本期较上一季度新披露的外资机构有 1 家 ，即BARCLAYS BANK PLC。 2025年8月26日，新光药业(300519.SZ)发布2025年半年度报告。截至2025年8月25日，共有4个机构投资 者披露持有新光药业A股股份，合计持股量达2911.93万股，占新光药业总股本的18.20%。其中，机构 投资者包括嵊州市和丰投资股份有限公司、中国民生银行股份有限公司-金元顺安元启灵活配置混合型 证券投资基金、BARCLAYS BANK PLC、中国建设银行股份有限公司-诺安多策略股票型证券投资基 金，机构投资者合计持股比例达18.20%。相较于上一季度，机构持股比例合计上涨了0.75个百分点。 公募基金方面，本期较上一期持股增加的公募基金共计1个，即金元顺安元启灵活配置混合，持股增加 占比小幅上涨。本期较上一季度新披露的公募基金共计1个，即诺安多策略混合A。本期较上一季未再 披露的公募基金共计1个，即汇添富中证中药ETF。 ...

Group 1 - Kanyuan Pharmaceutical (600557.SH) released its 2024 annual report on April 3, 2025, indicating that 125 institutional investors disclosed holding A-shares, totaling 292 million shares, which accounts for 50.25% of the total share capital [1] - The top ten institutional investors include Jiangsu Kanyuan Group Co., Ltd., Lianyungang Kangbeier Medical Equipment Co., Ltd., Central Huijin Asset Management Co., Ltd., and others, with a combined holding ratio of 47.38%, showing a decrease of 1.85 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, five funds reported a decrease in holdings compared to the previous quarter, with a total reduction of 1.49% [2] - A total of 111 new public funds were disclosed this period, including funds such as Rongtong Health Industry Flexible Allocation Mixed A/B and Southern CSI 1000 ETF [2] - Four public funds were not disclosed this period, including various funds under the Fangzheng Fubang brand [2]